Fidelity Parent FMR Reports 5.8% Stake In Guardant Health, Counting Warrants And Convertibles

FMR, run by Chair and CEO Abigail P. Johnson, reports 7.7 million Guardant shares as of September 30, held in the ordinary course of business.

Share
Fidelity Parent FMR Reports 5.8% Stake In Guardant Health, Counting Warrants And Convertibles

FMR, the parent of Fidelity, disclosed a passive 5.8% stake in Guardant Health, the cancer-testing company, in a Schedule 13G ownership filing on Thursday. The position totals 7,733,224.05 shares as of September 30, 2026, and Guardant shares fell about 9% in Thursday trading.

Who holds the shares

FMR LLC and Abigail P. Johnson, a director, chairman and chief executive of FMR, filed jointly. FMR reports sole voting power over 7,566,762.18 of the shares and no shared voting power. Johnson reports neither sole nor shared voting power over the stake.

The holdings are spread across Fidelity units listed in an exhibit, among them Fidelity Management & Research Company, FIAM and Fidelity Management Trust Company. The exhibit says members of the Johnson family are the predominant owners of FMR's Series B voting shares, which carry 49% of its voting power.

FMR certified that the shares were acquired and are held in the ordinary course of business, not to change or influence control of Guardant. The filing also says other persons have the right to receive dividends or sale proceeds from the stock, and none of them holds more than 5%. The 5.8% is measured on the filing's cover-page basis, which counts shares acquirable within 60 days.

A cancer-testing company in the spotlight

Guardant is a precision oncology company that makes blood and tissue tests for cancer. Its Shield blood test screens adults 45 and older at average risk for colorectal cancer, and its Guardant360 tests help choose treatments for advanced cancer.

Shares traded at $153.86 in Thursday trading, down about 9% from the prior close of $168.58, for a market value of $22.6 billion. The week brought other company news: Guardant said on November 3 that Shield won the 2026 Prix Galien USA Award for Best Medical Technology, and it added former Dexcom CEO Kevin Sayer to its board.

Third-quarter results next

Guardant's third-quarter report is the next scheduled catalyst. Zacks consensus forecasts revenue of $350.83 million, up 32.3% from a year earlier, and a loss of $0.29 per share.

Guardant's third-quarter results will show whether revenue reaches the Zacks consensus of $350.83 million.

Sources

More on Guardant Health

All Guardant Health (GH) coverage →